Loading...
•
Dec 31, 2022
Aytu BioScience Q2 2023 Earnings Report
Reported second consecutive quarter of positive Adjusted EBITDA and a 14% increase in total net revenue.
Key Takeaways
Aytu BioPharma reported a 14% increase in total net revenue to $26.3 million, driven by a 23% growth in the Rx segment, and achieved its second consecutive quarter of positive Adjusted EBITDA at $0.7 million. The company's strategic shift to focus on commercial business growth and cost reductions contributed to improved profitability.
Total net revenue increased by 14% year-over-year to $26.3 million.
Rx segment revenue grew by 23% year-over-year to $18.0 million.
Adjusted EBITDA was a positive $0.7 million, compared to $(7.6) million in the year-ago quarter.
Gross margins increased to 66% compared to 53% in the year-ago quarter.
Aytu BioScience
Aytu BioScience
Aytu BioScience Revenue by Segment
Revenue by Segment
Other Revenue
CapyFin.com Forward Guidance
Company expects to save over $20.0 million in projected future study costs as part of the Company’s indefinite suspension of its clinical development programs. The manufacturing transfer to a global contract manufacturer of the ADHD products remains on track to be completed in calendar 2023, and this transition is expected to further improve gross margins of Adzenys XR-ODT and Cotempla XR-ODT. The extension of the interest-only period will conserve cash and save the Company over $3 million in calendar 2023 principal payments by deferring those payments into 2024 and 2025.
Positive Outlook
- Expected savings of over $20.0 million from suspending clinical development programs.
- Manufacturing transfer of ADHD products to improve gross margins.
- Extension of interest-only period on senior secured loan to conserve cash.
- Expected savings of over $3 million in calendar 2023 principal payments.
- Focus on higher contribution margin online sales channels to improve segment profitability.
Challenges Ahead
- Net loss during the second quarter of fiscal 2023 was impacted by an impairment of $2.6 million relating to the pipeline development of the NT-502 development program.
- Revenues from the Consumer Health segment will likely be impacted as we phase out the direct mail channel and focus on OTC medicines and their e-commerce sales.
- Calendar year-end weather-related shipping delays that pushed ADHD Portfolio revenue into Q3
- Consumer Health revenue decreased of 3% over the year ago quarter
- Net loss for the second quarter of fiscal 2023 was $(6.7) million, or $(2.15) per share